Rapid Micro Biosystems (RPID) Current Deferred Revenue (2020 - 2026)

Rapid Micro Biosystems (RPID) has 7 years of Current Deferred Revenue data on file, last reported at $6.6 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 8.34% year-over-year to $6.6 million; the trailing twelve-month figure through Mar 2026 stood at $6.6 million (up 8.34% YoY), and the FY2025 full-year result was $4.7 million, down 28.27% from the prior year.
• Current Deferred Revenue rose to $6.6 million in Q1 2026, from $4.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $6.6 million in Q4 2024 to a low of $3.4 million in Q3 2022.
• A 5-year average of $5.2 million and a median of $5.4 million in 2024 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue jumped 42.39% in 2022 and declined 28.27% in 2025, its largest moves.
• Tracing RPID's Current Deferred Revenue over 5 years: stood at $4.7 million in 2022, then climbed by 26.94% to $6.0 million in 2023, then climbed by 10.48% to $6.6 million in 2024, then decreased by 28.27% to $4.7 million in 2025, then jumped by 39.42% to $6.6 million in 2026.
• Business Quant data shows RPID's Current Deferred Revenue at $6.6 million in Q1 2026, $4.7 million in Q4 2025, and $5.1 million in Q3 2025.